[1] |
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up[J].Diabetes Care, 2016,39: 686-693.
|
[2] |
Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality[J]. JAMA, 2015,313:45-53.
|
[3] |
Tinsley LJ, Kupelian V, D'Eon SA, et al. Association of glycemic control with reduced risk for large-vessel disease after more than 50 years of type 1 diabetes[J]. J Clin Endocrinol Metab, 2017,102:3704-3711.
|
[4] |
中国医师协会内分泌代谢科医师分会, 国家代谢性疾病临床医学研究中心(长沙). 糖尿病分型诊断中国专家共识[J].中国医师杂志,2022,24:161-178.
|
[5] |
中国医师协会内分泌代谢科医师分会. 2型糖尿病早期大血管病变无创性检查的专家共识[J].中国循环杂志,2014,29:167-171.
|
[6] |
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC)[J]. J Hypertens, 2007,25:1105-1187.
|
[7] |
Liu W, Han X, Wang Y, et al. Characteristics and ongoing autoimmunity of patients with long-standing type 1 diabetes living in China[J]. Diabetes Care, 2018,41:e97-e98.
|
[8] |
Secrest AM, Becker DJ, Kelsey SF, et al. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry[J]. Diabetes Care, 2010,33:2573-2579.
|
[9] |
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Risk factors for cardiovascular disease in type 1 diabetes[J]. Diabetes, 2016,65:1370-1379.
|
[10] |
Bebu I, Keshavarzi S, Gao X, et al. Genetic risk factors for CVD in type 1 diabetes: the DCCT/EDIC study[J]. Diabetes Care, 2021,44:1309-1316.
|
[11] |
Catarino D, Silva D, Guiomar J, et al. Non-immune-mediated versus immune-mediated type 1 diabetes: diagnosis and long-term differences-retrospective analysis[J]. Diabetol Metab Syndr, 2020,12:56. doi:10.1186/s13098-020-00563-x.
|
[12] |
Sousa GR, Pober D, Galderisi A, et al. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus[J]. Circulation, 2019,139:730-743.
|